Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPYD | Q12882 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HBB | P68871 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17060269 | 0.80 | DPYD (0.52) | DPYDGAAATAD2ALDH1A1LMNA | |
| SCHEMBL3485396 | 0.77 | ATAD2 (0.44) | DPYDATAD2 | |
| SCHEMBL4353311 | 0.76 | DPYD (0.50) | DPYDGAAATAD2ALDH1A1LMNA | |
| SCHEMBL5800398 | 0.76 | — | — | |
| SCHEMBL161148 | 0.74 | ATAD2 (0.54) | DPYDGAAATAD2ALDH1A1LMNA | |
| SCHEMBL3699779 | 0.73 | DPYD (0.43) | DPYDGAAATAD2ALDH1A1LMNA | |
| SCHEMBL5798297 | 0.72 | DPYD (0.46) | DPYDGAAATAD2ALDH1A1LMNA | |
| SCHEMBL44459 | 0.72 | GAA (0.52) | DPYDGAAATAD2ALDH1A1LMNA | |
| SCHEMBL2584919 | 0.72 | LMNA (0.52) | DPYDGAAATAD2ALDH1A1LMNA | |
| SCHEMBL2037916 | 0.72 | DPYD (0.46) | DPYDGAAATAD2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802645-B2 | Molecule for treating an inflammatory disorder | PROSENSA TECHNOLOGIES B.V. (NL) | 2014-08-12 | — | — | US | claimed |
| CN-103221055-A | Modulation of TIMP1 and TIMP2 expression | NITTO DENKO CORP | 2013-07-24 | — | — | CN | claimed |
| EP-4692338-A1 | CAS12 PROTEIN AND USE THEREOF | Guangzhou Reforgene Medicine Co., Ltd. (CN) | 2026-02-11 | — | — | EP | disclosed |
| US-20260009052-A1 | CAS12 PROTEINS AND USES THEREOF | GUANGZHOU REFORGENE MEDICINE CO., LTD. (CN) | 2026-01-08 | — | — | US | disclosed |
| CN-120077133-A | IL-4RA targeting splice switching oligonucleotides | 新加坡科技研究局 | 2025-05-30 | — | — | CN | disclosed |
| CN-119730859-A | RNAi agents for inhibiting superoxide dismutase 1 (SOD 1) expression, compositions and methods of use thereof | 箭头药业股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119464283-A | Capped mRNA and method of making same | 苏州艾博生物科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-111448316-B | Novel thiophosphorous acid amides | 罗氏创新中心哥本哈根有限公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-118792301-A | Compositions and methods for inhibiting TMPRSS6 gene expression | 阿尔尼拉姆医药品有限公司 | 2024-10-18 | — | — | CN | disclosed |
| CN-118647397-A | Polynucleotide composition and use thereof | 辉瑞公司 | 2024-09-13 | — | — | CN | disclosed |
| US-20240271140-A1 | LPA INHIBITOR AND USE THEREOF | CHENGDU XINZHENGHE PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) | 2024-08-15 | — | — | US | disclosed |
| CN-106470688-A | Oligomers and oligomer conjugates | 豪夫迈·罗氏有限公司 | 2017-03-01 | — | — | CN | disclosed |
| CN-106414739-A | Improved exon skipping compositions for the treatment of muscular dystrophy | 萨雷普塔医疗公司 | 2017-02-15 | — | — | CN | disclosed |
| EP-2516647-B1 | Molecule for treating an inflammatory disorder | BIOMARIN TECH BV (NL) | 2016-12-14 | — | — | EP | disclosed |
| US-8802645-B2 | Molecule for treating an inflammatory disorder | PROSENSA TECHNOLOGIES B.V. (NL) | 2014-08-12 | — | — | US | disclosed |
| CN-103813810-A | Compositions and methods for inhibiting expression of TMPRSS6 gene | ALNYLAM PHARMACEUTICALS INC | 2014-05-21 | — | — | CN | disclosed |
| CN-103221055-A | Modulation of TIMP1 and TIMP2 expression | NITTO DENKO CORP | 2013-07-24 | — | — | CN | disclosed |
| EP-2516647-A1 | MOLECULE FOR TREATING AN INFLAMMATORY DISORDER | Prosensa Technologies B.V. (NL) | 2012-10-31 | — | — | EP | disclosed |
| US-20120259002-A1 | MOLECULE FOR TREATING AN INFLAMMATORY DISORDER | Acedemisch Ziekenhuis Leiden h.o.d.n. LUMC (NL) | 2012-10-11 | — | — | US | disclosed |
| WO-2011078672-A1 | MOLECULE FOR TREATING AN INFLAMMATORY DISORDER | PROSENSA TECHNOLOGIES B.V. (NL) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260009052-A1 | CAS12 PROTEINS AND USES THEREOF | RBM12, STING1, TTLL12 | DPYD 4238/4885GAA 2427/4885ATAD2 875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.